H.C. Wainwright assumed coverage of Evotec with a Buy rating and $7 price target. The company's has transformed from a legacy asset-heavy integrated model toward a leaner and capital-efficient structure, the analyst tells investors in a research note. The firm sees current share levels as an attractive entry point for a long-term investor.
